Intermediate-stage hepatocellular carcinoma (HCC) encompasses a diverse patient population that requires individualized treatment strategies and a multidisciplinary approach. Recent advancements in systemic therapy have expanded the therapeutic options for intermediate-stage HCC, allowing for combination strategies such as systemic therapy with transarterial chemoembolization (TACE) and upfront systemic therapy for individuals deemed unsuitable for TACE. Additionally, the ongoing development of treatment modalities for intermediate-stage HCC has improved the potential for curative conversion and tumor downstaging. Nevertheless, consensus on the optimal management of intermediate-stage HCC remains limited. Thus, the primary aim of this study was to develop a set of consensus guidelines for the management of intermediate-stage HCC. To address this gap, the Taiwan Liver Cancer Association (TLCA) established a working group to develop a multidisciplinary strategy for managing intermediate-stage HCC. Here, we present eight consensus statements formulated by this expert panel, which outline criteria for TACE unsuitability, treatment recommendations based on TACE eligibility, and considerations for various modalities, including conventional TACE, drug-eluting bead TACE, and transarterial radioembolization, as well as the appropriate timing for initiating systemic therapy to enable curative conversion and downstaging. These statements provide specific, evidence-based recommendations for clinicians, addressing treatment pathways based on TACE eligibility and other key considerations for intermediate-stage HCC management. The development of this consensus guideline is intended to aid clinicians in selecting the most appropriate treatment pathway for intermediate-stage HCC, support personalized treatment planning, and ultimately enhance the feasibility of achieving curative conversion.
Background/Aims The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C, remains largely uncertain. We aimed to explore the impact of DAA therapy on overall survival (OS) in HCC patients using a nationwide cohort study.
Methods We utilized the nationwide Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) database to include all adults receiving a DAA therapy for HCV, excluding those with other viral infections, liver transplantation, non-HCC malignancies, and terminal-staged HCC. We respectively analyzed the adjusted odds ratio (aOR) for sustained virological response (SVR) and adjusted hazard ratio (aHR) for OS.
Results Between December 2013 and December 2020, 2,205 (9.3%) patients with HCC and 21,569 (90.7%) patients without HCC were include. The SVR rates were 96.6% in the HCC group and 98.8% in the non-HCC group (P<0.001), with HCC being an independent risk factor affecting SVR (aOR 0.41; 95% CI 0.31–0.54; P<0.001). In the whole patient cohort, SVR was independently associated with improved OS (aHR 0.46; 95% CI 0.35–0.60; P<0.001). Among patients with baseline HCC, SVR remained an independent factor related to OS (aHR 0.41; 95% CI 0.28–0.59; P<0.001). The impact of SVR on OS persisted significantly across BCLC stages 0/A and stages B/C.
Conclusions High SVR rates among HCC patients underscore the importance of DAA therapy in enhancing OS, reaffirming its efficacy across various HCC stages.
Citations
Citations to this article as recorded by
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai European Journal of Cancer.2026; 232: 116109. CrossRef
Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Background/Aims Treatment indications for patients with chronic hepatitis B (CHB) remain contentious, particularly for patients with mild alanine aminotransferase (ALT) elevation. We aimed to evaluate treatment effects in this patient population.
Methods This rollover study extended a placebo-controlled trial that enrolled non-cirrhotic patients with CHB and ALT levels below two times the upper limit of normal. Following 3 years of randomized intervention with either tenofovir disoproxil fumarate (TDF) or placebo, participants were rolled over to open-label TDF for 3 years. Liver biopsies were performed before and after the treatment to evaluate histopathological changes. Virological, biochemical, and serological outcomes were also assessed (NCT02463019).
Results Of 146 enrolled patients (median age 47 years, 80.8% male), 123 completed the study with paired biopsies. Overall, the Ishak fibrosis score decreased in 74 (60.2%), remained unchanged in 32 (26.0%), and increased in 17 (13.8%) patients (p<0.0001). The Knodell necroinflammation score decreased in 58 (47.2%), remained unchanged in 29 (23.6%), and increased in 36 (29.3%) patients (p=0.0038). The proportion of patients with an Ishak score ≥ 3 significantly decreased from 26.8% (n=33) to 9.8% (n=12) (p=0.0002). Histological improvements were more pronounced in patients switching from placebo. Virological and biochemical outcomes also improved in placebo switchers and remained stable in patients who continued TDF. However, serum HBsAg levels did not change and no patient cleared HBsAg.
Conclusions In CHB patients with minimally raised ALT, favorable histopathological, biochemical, and virological outcomes were observed following 3-year TDF treatment, for both treatment-naïve patients and those already on therapy.
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers.
Citations
Citations to this article as recorded by
Surveillance for Hepatocellular Carcinoma in Cirrhosis: End of Monopoly for Serum Alpha Fetoprotein Lung-Yi Mak, Man-Fung Yuen Gastroenterology.2025; 168(2): 217. CrossRef
Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies Jinlin Hou, Thomas Berg, Arndt Vogel, Teerha Piratvisuth, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Katarina Malinowsky, Peter Findeisen, Johannes Kolja Hegel, Wenzel Schöning, Kairat Madin, Konstantin Kroeniger, Henry Lik-Yuen Chan, Ashish Sharma JHEP Reports.2025; 7(2): 101263. CrossRef
Establishment of sex-specific reference intervals for PIVKA-II in Southwest China: A real-world data analysis Bin Wei, Yalin Zheng, Lixin Li, Limei Luo, Ying Guo Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2025; 62(3): 202. CrossRef
Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study Hwa‐Hee Koh, Minyu Kang, Deok‐Gie Kim, Jae Hyon Park, Eun‐Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo Journal of Gastroenterology and Hepatology.2025; 40(3): 626. CrossRef
Rapid evaluation of hepatocellular carcinoma by detecting plasma exosomes with time-resolved fluorescence immunochromatographic test strips Jiaming Li, Jianfen Su, Minghui Li, Yaofen Wu, Huiqiang Chen, Xihua Fu, Hongliang Yao, Jinping Chen, Yuntao Liu, Jie Zan Microchimica Acta.2025;[Epub] CrossRef
Prognostic Value of the ASAP Score for Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multicenter Analysis of 1,239 Patients Tian Yang, Dong-Xu Yin, Yong-Kang Diao, Ming-Da Wang, Xian-Ming Wang, Yong-Yi Zeng, Zhong Chen, Han Liu, Fu-Jie Chen, Yu-Chen Li, Jia-Hao Xu, Han Wu, Lan-Qing Yao, Xin-Fei Xu, Chao Li, Li-Hui Gu, Alfred W. Chieh Kow, Timothy M. Pawlik, Feng Shen Journal of Clinical and Experimental Hepatology.2025; 15(3): 102497. CrossRef
Predicting hepatocellular carcinoma outcomes and immune therapy response with ATP-dependent chromatin remodeling-related genes, highlighting MORF4L1 as a promising target Chao Xu, Litao Liang, Guoqing Liu, Yanzhi Feng, Bin Xu, Deming Zhu, Wenbo Jia, Jinyi Wang, Wenhu Zhao, Xiangyu Ling, Yongping Zhou, Wenzhou Ding, Lianbao Kong Cancer Cell International.2025;[Epub] CrossRef
Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study Yoshitaka Saegusa, Yuki Imaoka, Masahiro Ohira, Tsuyoshi Kobayashi, Naruhiko Honmyo, Michinori Hamaoka, Takashi Onoe, Daisuke Takei, Koichi Oishi, Tomoyuki Abe, Toshihiro Nakayama, Miho Akabane, Kazunari Sasaki, Hideki Ohdan Journal of Gastrointestinal Surgery.2025; 29(4): 101980. CrossRef
3D synergistic tumor-liver analysis further improves the efficacy prediction in hepatocellular carcinoma: a multi-center study Yurong Jiang, Jiawei Zhang, Zhaochen Liu, Jinxiong Zhang, Xiangrong Yu, Danyan Lin, Dandan Dong, Mingyue Cai, Chongyang Duan, Shuyi Liu, Wenhui Wang, Yuan Chen, Qiyang Li, Weiguo Xu, Meiyan Huang, Sirui Fu BMC Cancer.2025;[Epub] CrossRef
Teaching design for chapter “primary liver cancer” in surgery course based on the clinical theory and clerkship synchronization model in the era of New Medicine Feng Ye, Qiang Cai, Xiaoyong Gong, Jiajun Ren, Ruixin Sun, Chang Liu, Xiaoli Wang, Yuan Qiao Global Medical Education.2025;[Epub] CrossRef
Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS) Tonghui Lu, Kailing Xie, Yan Chen, Mingxiu Ma, Yaming Guo, Tianqiang Jin, Chaoliu Dai, Feng Xu European Journal of Surgical Oncology.2025; 51(6): 109677. CrossRef
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination Grace Lai-Hung Wong, Henry Lik-Yuen Chan Hepatology.2025; 82(5): 1056. CrossRef
CA19-9, CEA and PIVKA-Ⅱ as a novel panel of serum markers for diagnosis of pancreatic cancer Meifang Wang, Hongying Bu, Weijia Luo, Xi Zeng, Guodong Chen, Yingchun He, Deliang Cao Clinical Biochemistry.2025; 137: 110902. CrossRef
Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection Zhan-Cheng Qiu, You-Wei Wu, Jun-Long Dai, Wei-Li Qi, Chu-Wen Chen, Yue-Qing Xu, Jun-Yi Shen, Chuan Li, Tian-Fu Wen Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
The Diagnostic Performance of AFP, AFP-L3, DCP, CA199, and Their Combination for Primary Liver Cancer Yue Liu, Wenrong Jiang, Xiangxiao Li, Hu Zhao, Shiwen Wang Journal of Hepatocellular Carcinoma.2025; Volume 12: 513. CrossRef
5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation Danjun Song, Zhou Zhang, Jiaping Zheng, Wei Zhang, Jiabin Cai Biomarker Research.2025;[Epub] CrossRef
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation Xinting Pan, Yang Zhou, Zhenli Li, Pengfei Guo, Jianyang Zeng, Xiuqing Dong, En Hu, Liman Qiu, Zhixiong Cai, Geng Chen, Xiaolong Liu Communications Medicine.2025;[Epub] CrossRef
Assessing the Validity of the AASLD Surgical Treatment Algorithm in Patients with Early-Stage Hepatocellular Carcinoma Aryoung Kim, Byeong Geun Song, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh, Dong Hyun Sinn Gut and Liver.2025; 19(2): 265. CrossRef
Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia Clinical and Molecular Hepatology.2025; 31(Suppl): S285. CrossRef
Key prognostic factors in transarterial chemoembolization combined with sorafenib treatment for hepatocellular carcinoma with portal vein tumor thrombosis Zilun Lei American Journal of Cancer Research.2025; 15(2): 517. CrossRef
Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers Tian Yang, Mingda Wang, Nanya Wang, Mingxin Pan, Yu Xu, Qiancheng You, Lanqing Yao, Jiahao Xu, Lihui Gu, Xiaodong Sun, Lei Zhang, Jiayue Xu, Bingsi Li, Guoqiang Wang, Shangli Cai, Guoyue Lv, Feng Shen Advanced Science.2025;[Epub] CrossRef
Paracancerous binuclear hepatocytes assessed by computer program is a novel biomarker for short term recurrence of hepatocellular carcinoma after surgery Yifan Zhang, Yiquan Lu, Nan Wang, Fengjie Hao, Yongjun Chen, Xiaochun Fei, Junqing Wang Scientific Reports.2025;[Epub] CrossRef
Preoperative identification of hepatocellular carcinoma from focal liver lesions ≤ 20 mm in high-risk patients using clinical and contrast-enhanced ultrasound features Xin-Yuan Hu, Yi-Kang Sun, Yao Miao, Xiao-Ling Chen, Dan Lu, Bo-Yang Zhou, Li-Fan Wang, Chong-Ke Zhao, Hao-Hao Yin, Xiao-Long Li, Zi-Tong Chen, Ya-Qin Zhang, Ming-Rui Zhu, Xin Guan, Er-Xuan Wu, Hong Han, Li-Ping Sun, Qing Lu, Hui-Xiong Xu European Journal of Radiology.2025; 187: 112076. CrossRef
Plasma methylated HIST1H3G as a non-invasive biomarker for diagnostic modeling of hepatocellular carcinoma Weiwei Zhu, Huifen Wang, Yudie Cai, Jun Lei, Jia Yu, Ang Li, Zujiang Yu Frontiers in Medicine.2025;[Epub] CrossRef
Postoperative regular follow-up in hepatocellular carcinoma: Transforming early detection into survival gains Alfred Wei Chieh Kow Hepatobiliary & Pancreatic Diseases International.2025; 24(3): 237. CrossRef
New insights into biomarkers and risk stratification to predict hepatocellular cancer Katrina Li, Brandon Mathew, Ethan Saldanha, Puja Ghosh, Adrian R. Krainer, Srinivasan Dasarathy, Hai Huang, Xiyan Xiang, Lopa Mishra Molecular Medicine.2025;[Epub] CrossRef
The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment Jiayun Jiang, Hui Zhang, Yanjiao Ou, Jiejuan Lai, Yulan Huang, Wenyun Cai, Chong Li, Leida Zhang, Yu Fu Immunology Letters.2025; 275: 107003. CrossRef
HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies Fouad Jaber, Hashem B. El-Serag Hepatic Oncology.2025;[Epub] CrossRef
Integrated spatial and single cell transcriptomics identifies PRKDC as a dual prognostic biomarker and therapeutic target in hepatocellular carcinoma Wenpeng Pang, Yunyong Wang, Xiaohang Lu, Minpeng Li, Fuli Long, Songlin Chen, Yuan Yu, Mingfen Li, Hongsheng Lin Scientific Reports.2025;[Epub] CrossRef
Hepatocellular Carcinoma: The Search for an Optimal Screening Test Sara Haj Ali, Shahd I Alqato, Amjad M Almansi, Noor S Haj Ali, Mohammad A Amaireh Middle East Journal of Digestive Diseases.2025; 17(1): 31. CrossRef
Invited commentary on “Tumor biology characteristics score based on alpha-fetoprotein and prothrombin induced by vitamin K absence-II predicts recurrence and survival after curative resection for hepatocellular carcinoma: a multicenter cohort study” Abu Bakar Hafeez Bhatti Journal of Gastrointestinal Surgery.2025; 29(7): 102076. CrossRef
Development of a chitosanase 3-like protein 1 assay kit and study of its application in patients with hepatocellular carcinoma Min Liu, Yanru Qiu, Erfu Xie, Pu Qian, Shuxian Yang, Simin Zhao, Wenjun Yan, Xuan Huang, Shuang Han BMC Biotechnology.2025;[Epub] CrossRef
Predictability of clinical outcomes after external beam radiotherapy for hepatocellular carcinoma according to tumor marker dynamics Sunmin Park, Chai Hong Rim, Young Kul Jung, Hyung Joon Yim, Hwan Hoon Chung, Won Sup Yoon, Gregory Tiao PLOS One.2025; 20(5): e0323450. CrossRef
Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report Xiaodong Zhang, Luyi Zhang, Shuangying Zhao, Lingling Dai, Huayu Li, Xudong Wu, Huanjun Yan, Rongfeng Lin, Kelei Zhu Frontiers in Immunology.2025;[Epub] CrossRef
Current and new strategies for hepatocellular carcinoma surveillance Natchaya Polpichai, Chongkonrat Maneenil, Pojsakorn Danpanichkul, Chitchai Rattananukrom, Ashok Choudhury, Yu Jun Wong, Pimsiri Sripongpun, Suthat Liangpunsakul, Apichat Kaewdech Gastroenterology Report.2025;[Epub] CrossRef
Alpha-fetoprotein: A Multifaceted Player in Cancer Biology Mete Ucdal, Yigit Yazarkan, Gamze Sonmez, Basak Celtikci, Yasemin Balaban Euroasian journal of hepato-gastroenterology.2025; 15(1): 72. CrossRef
Erratum to “Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study” [J Gastrointest Surg 29 (2025) 101980] Yoshitaka Saegusa, Yuki Imaoka, Masahiro Ohira, Tsuyoshi Kobayashi, Naruhiko Honmyo, Michinori Hamaoka, Takashi Onoe, Daisuke Takei, Koichi Oishi, Tomoyuki Abe, Toshihiro Nakayama, Miho Akabane, Kazunari Sasaki, Hideki Ohdan Journal of Gastrointestinal Surgery.2025; 29(8): 102129. CrossRef
Hepatocellular Carcinoma: Review of Indian Literature Vaishnavi Konda, Shanthi Vijayaraghavan Gastroenterology, Hepatology and Endoscopy Practice.2025; 5(3): 95. CrossRef
Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study Saran Ochir Gongor, YoungRok Choi, Gayoung Kim, Min Kyoung Kim, Sang Hyuk Park, Jiyoung Kim, Jae-Yoon Kim, Su young Hong, Jeong-Moo Lee, Suk Kyun Hong, Kwang-Woong Lee Transplant International.2025;[Epub] CrossRef
Prothrombin-induced by vitamin K absence II as a prognostic factor in living donor liver transplantation for hepatocellular carcinoma Abu Bakar Hafeez Bhatti, Usman Shafique, Nazish Ahmed, Ghazanfar Abbas, Muslim Atiq, Haseeb Haider Zia, Nusrat Yar Khan, Atif Rana Scientific Reports.2025;[Epub] CrossRef
Evaluation of serum hsa_tsr014055 as a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma Jing Xu, Bairong Chen, Jing Qi, Jinran Wu, Wei Feng, Kangfeng Jin, Hongyi Bao, Lin Chen, Feng Wang Annals of Medicine.2025;[Epub] CrossRef
Global, regional, and national burden of liver cancer due to hepatitis B, 1990–2021 and projections to 2051: a systematic analysis of the Global Burden of Disease Study 2021 Peipei Yang, Wenjie Huang, Yuanyuan Xu, Qiurong Li, Xinyan Shu, Jiaqian Zuo, Wenqin Ren, Yujie Huang, Yuhao Teng, Peng Shu European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Differential Associations of PIVKA-II with Epithelial and Mesenchymal Features in HCC and PDAC Antonella Farina, Gaia Cicolani, Valentina Viggiani, Matteo Maini, Antonio Angeloni, Emanuela Anastasi International Journal of Molecular Sciences.2025; 26(15): 7581. CrossRef
Preoperative ASAP score predicts recurrence and survival following curative hepatic resection for hepatitis B virus-related hepatocellular carcinoma: A multicenter cohort study Dongxu Yin, Zixuan Wang, Chao Li, Huixuan Fan, Zichao Tu, Yongkang Diao, Zijie Tang, Yongyi Zeng, Han Wu, Lihui Gu, Lanqing Yao, Xinfei Xu, Feng Shen, Mingda Wang, Tian Yang European Journal of Surgical Oncology.2025; 51(10): 110361. CrossRef
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Sex disparity in hepatocellular carcinoma recurrence after curative liver resection: a multicenter comprehensive analysis Mu-Gen Dai, Si-Yu Liu, Qing Xu, Wen-Feng Lu, Lei Liang, Jun-Wei Liu, Kun Zhang, Bin Ye European Journal of Gastroenterology & Hepatology.2025; 37(11): 1275. CrossRef
Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort Thuy Thi Thu Pham, Dat Tan Ho, Toan Bao Nguyen, Hai Thanh Phan Discover Oncology.2025;[Epub] CrossRef
Targeting glypican-3 as a new frontier in liver cancer therapy Chen-Shiou Wu, Teng-Yu Lee, Hsu-Wen Chao World Journal of Hepatology.2025;[Epub] CrossRef
Early PIVKA-II Response Associated with Treatment Efficacy and Survival Outcomes for Patients with Advanced Hepatocellular Carcinoma Receiving Immune Checkpoint Inhibitors and Targeted Therapy Zheng-Kang Fang, Yu-Ting Xiao, Xia Feng, Zhe-Jin Shi, Si-Yu Liu, Yang Yu, Li-Ming Jin, Dong-Sheng Huang, Cheng-Wu Zhang, Jun-Wei Liu, Lei Liang Journal of Hepatocellular Carcinoma.2025; Volume 12: 2235. CrossRef
Nanomaterial-Mediated Electrochemical and Optical Biosensors and Their Application in Tumour Marker Detection Xinlan Wang, Jingyi Hei, Tao Zhao, Xiyu Liu, Yong Huang Sensors.2025; 25(18): 5902. CrossRef
Combined Analysis of Protein Induced by Prothrombin Induced by Vitamin K Absence (PIVKA) and Alpha-L-Fucosidase (AFU) with Alpha-Fetoprotein (AFP) May Improve the Diagnostic Efficacy for Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Haisong Hou, Ruiqiang Weng, Liu Liang, Wendao Han International Journal of General Medicine.2025; Volume 18: 6031. CrossRef
Leveraging artificial intelligence to validate traditional biomarkers and drug targets in liver cancer recovery: a mini review Shengjian Wu, Xiaoqiao Chen, Yuxiu Ji, Chi Zhang, Yujie Xie, Bin Liang Frontiers in Pharmacology.2025;[Epub] CrossRef
Pilot Study of PIVKA-II in the Prognostic Assessment of Hepatocellular Carcinoma in Chronic Viral Hepatitis: Comparative Findings from HBV and HCV Cohorts from a Single Center in Serbia Ivana Milošević, Nataša Nikolić, Sanja Stanković, Ana Filipović, Jovana Ranin, Irena Paunović, Jelena Simić, Branko Beronja Biomedicines.2025; 13(11): 2653. CrossRef
Clinical Implications and Novel Insights into Adolescent Primary Liver Cancer: A Nightmare for Adolescents? Huidong Guo, Xiaojun Chen, Rong Li, Jianzhen Shen, Donghui Gan, Yue Yin, Hehui Zhang, Jiachen Xie, Longfei Xie, Yanquan Liu Journal of Hepatocellular Carcinoma.2025; Volume 12: 2513. CrossRef
MRI-based 2.5D deep learning and radiomics effectively predicted microvascular invasion and Ki-67 expression in hepatocellular carcinoma Hongmei Yu, Depeng Kong, Xiaojun Mo, Ju Huang, Jie Wu, Yang Wang, Feizhou Du, Nima Broomand Lomer, PLOS One.2025; 20(11): e0336579. CrossRef
5’-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma Jie Yuan, Wen-Chao Gu, Tian-Xin Xu, Xian-Juan Shen, Xian Li, Lei Shen, Yan Zhang, Shao-Qing Ju World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Protein Induced by Vitamin K Absence or Antagonist‐II: Significantly Elevated in Obstructive Jaundice and Sepsis Patients Without Hepatocellular Carcinoma Ke Zhang, Xiarui Ye, Xianran Fu Journal of Clinical Laboratory Analysis.2025;[Epub] CrossRef
Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein Quirino Lai, Takashi Ito, Samuele Iesari, Toru Ikegami, Daniele Nicolini, Zoe Larghi Laureiro, Massimo Rossi, Marco Vivarelli, Tomoharu Yoshizumi, Etsurou Hatano, Jan Lerut Liver Transplantation.2024; 30(5): 472. CrossRef
PIVKA‐II combined with tumor burden score to predict long‐term outcomes of AFP‐negative hepatocellular carcinoma patients after liver resection Zhan‐cheng Qiu, You‐wei Wu, Wei‐li Qi, Chuan Li Cancer Medicine.2024;[Epub] CrossRef
Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma Ming-Da Wang, Yong-Kang Diao, Lan-Qing Yao, Zhong-Qi Fan, Ke-Chun Wang, Han Wu, Li-Hui Gu, Jia-Hao Xu, Chao Li, Guo-Yue Lv, Tian Yang iLIVER.2024; 3(1): 100083. CrossRef
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan Wei Teng, Hung-Wei Wang, Shi-Ming Lin Liver Cancer.2024; 13(5): 468. CrossRef
Development of a Reliable GADSAH Model for Differentiating AFP-negative Hepatic Benign and Malignant Occupying Lesions Xiaoling Long, Huan Zeng, Yun Zhang, Qiulong Lu, Zhao Cao, Hong Shu Journal of Hepatocellular Carcinoma.2024; Volume 11: 607. CrossRef
Celestial Insights: Unraveling the Role of miR-3682-3p in Hepatocellular Carcinoma Pei-Dong Miao, Ying Li, Yu-Dong Jiang Clinical and Translational Gastroenterology.2024; 15(4): e00690. CrossRef
Research progress of protein induced by vitamin K absence or antagonist II in liver transplantation for hepatocellular carcinoma Zheyu Zhou, Qiaoyu Liu, Jinsong Liu, Wenwen Li, Shuya Cao, Jiawei Xu, Jun Chen, Xiaoliang Xu, Chaobo Chen Heliyon.2024; 10(9): e30622. CrossRef
Optimizing care of HBV infection and HBV-related HCC Shi Yan Lee, Benjamin Kai Yi Nah, Jazleen Leo, Jia Hong Koh, Daniel Q. Huang Clinical Liver Disease.2024;[Epub] CrossRef
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim Clinical and Molecular Hepatology.2024; 30(3): 360. CrossRef
Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients Mingda Wang, Guojun Qian, Hongmei Xiao, Xingkai Liu, Liyang Sun, Zhong Chen, Kongying Lin, Lanqing Yao, Chao Li, Lihui Gu, Jiahao Xu, Xiaodong Sun, Wei Qiu, Timothy M Pawlik, Wan Yee Lau, Guoyue Lv, Feng Shen, Tian Yang The Oncologist.2024; 29(12): e1723. CrossRef
The ARH score, a practical guide to decision-making for retreatment with hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients Jie Mei, Chengyou Yu, Feng Shi, Renguo Guan, Shaohua Li, Chong Zhong, Rongping Guo, Wei Wei International Immunopharmacology.2024; 138: 112551. CrossRef
Monocyte distribution width as a promising biomarker for differential diagnosis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma Sheng Lin, Xinyao Yang, Xin Yang, Minjie Tang, Xiaobao Yao, Yuchen Ye, Qunfang Huang, Jinlan Huang, Jiejuan Li, Qiang Yi, Wennan Wu, Shiqi Li, Yaru Lei, Bin Yang, Can Liu, Qishui Ou, Zhen Xun Frontiers in Immunology.2024;[Epub] CrossRef
Hepatocellular Carcinoma in Asia: Physician and Patient Perspectives on Surveillance, Diagnosis, and Treatment Rosmawati Mohamed, Wendy Wang, Tawesak Tanwandee, Irsan Hasan, Cam Phuong Pham, Young-Suk Lim, Sheng-Nan Lu, Murallitharan Munisamy, Thi Thanh Huong Tran, Evy Ratnawati, Wattana Sukeepaisarnjaroen, Mahir Karababa, Chee-Kiat Tan Journal of Gastrointestinal Cancer.2024; 55(3): 1333. CrossRef
Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma Ji Yeon Lee, Pil Soo Sung Gut and Liver.2024; 18(4): 558. CrossRef
Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Shang-Yu Lu, Han-Yao Sun, Yan Zhou, Xi Luo, Sheng Liu, Wei-Zhong Zhou, Hai-Bin Shi, Wei Yang, Wei Tian Journal of Hepatocellular Carcinoma.2024; Volume 11: 1979. CrossRef
CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients Rong Wen, Yuting Peng, Yiqiong Liang, Yuquan Wu, Haiyuan Li, Yanxia Chen, Yan Qin, Zhiyuan Wen, Huanyu Cui, Yun He, Hong Yang Ultrasound in Medicine & Biology.2024; 50(11): 1739. CrossRef
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma Lung-Yi Mak Journal of Liver Cancer.2024; 24(2): 145. CrossRef
Construction and evaluation of a liver cancer risk prediction model based on machine learning Ying-Ying Wang, Wan-Xia Yang, Qia-Jun Du, Zhen-Hua Liu, Ming-Hua Lu, Chong-Ge You World Journal of Gastrointestinal Oncology.2024; 16(9): 3839. CrossRef
Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study Shuya Cao, Zheyu Zhou, Chaobo Chen, Wenwen Li, Jinsong Liu, Jiawei Xu, Chunlong Zhao, Yihang Yuan, Zhenggang Xu, Huaiyu Wu, Guwei Ji, Xiaoliang Xu, Ke Wang World Journal of Surgical Oncology.2024;[Epub] CrossRef
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma Yau-Tuen Chan, Cheng Zhang, Junyu Wu, Pengde Lu, Lin Xu, Hongchao Yuan, Yibin Feng, Zhe-Sheng Chen, Ning Wang Molecular Cancer.2024;[Epub] CrossRef
Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma Tong-Guo Miao, Shi-Ya Zhang, Yun-Jing Zhang, Dong Ma, Yue-Min Nan Scientific Reports.2024;[Epub] CrossRef
Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma Minami Yamauchi, Masamitsu Maekawa, Toshihiro Sato, Yu Sato, Masaki Kumondai, Mio Tsuruoka, Jun Inoue, Atsushi Masamune, Nariyasu Mano Metabolites.2024; 14(9): 513. CrossRef
Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study Xi Wang, Xinqun Chai, Ruiya Tang, Yunjie Xu, Qinjunjie Chen Updates in Surgery.2024; 76(8): 2755. CrossRef
Multi-stage mechanisms of tumor metastasis and therapeutic strategies Zaoqu Liu, Jingqi Chen, Yuqing Ren, Shutong Liu, Yuhao Ba, Anning Zuo, Peng Luo, Quan Cheng, Hui Xu, Xinwei Han Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study Soon Kyu Lee, Soon Woo Nam, Ji Won Han, Jung Hyun Kwon Cancers.2024; 16(20): 3543. CrossRef
Prediction of microvascular invasion in hepatocellular carcinoma with conventional ultrasound, Sonazoid-enhanced ultrasound, and biochemical indicator: a multicenter study Dan Lu, Li-Fan Wang, Hong Han, Lin-Lin Li, Wen-Tao Kong, Qian Zhou, Bo-Yang Zhou, Yi-Kang Sun, Hao-Hao Yin, Ming-Rui Zhu, Xin-Yuan Hu, Qing Lu, Han-Sheng Xia, Xi Wang, Chong-Ke Zhao, Jian-Hua Zhou, Hui-Xiong Xu Insights into Imaging.2024;[Epub] CrossRef
Cross-sectional study on the diagnostic significance of plasma exosomal miRNAs in HBV-related hepatocellular carcinoma Xiaoyuan Hu, Fa Huang, Jiyou Yao, Jiaxian Lv, Jialuo Mai, Ning Li, Minqiang Lu Journal of Translational Medicine.2024;[Epub] CrossRef
Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy Teng Zhang, Wengang Li, Qian Chen, Weiping He, Jing Sun, Dong Li, Quan Wang, Xuezhang Duan Frontiers in Immunology.2024;[Epub] CrossRef
Evolution of Liver Resection for Hepatocellular Carcinoma: Change Point Analysis of Textbook Outcome over Twenty Years Yeshong Park, Ho-Seong Han, Seung Yeon Lim, Hyelim Joo, Jinju Kim, MeeYoung Kang, Boram Lee, Hae Won Lee, Yoo-Seok Yoon, Jai Young Cho Medicina.2024; 61(1): 12. CrossRef
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study Yi Jiang, Ke Su, Han Li, Chenjie Wang, Zhenying Wu, Jiali Chen, Zhiyao Zhang, Kun He, Yunwei Han Investigational New Drugs.2024;[Epub] CrossRef
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea? Min Kyung Park, Yoon Jun Kim Clinical and Molecular Hepatology.2023; 29(2): 332. CrossRef
Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan San-Chi Chen Clinical and Molecular Hepatology.2023; 29(2): 352. CrossRef
Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers Shu An, Xiaoxia Zhan, Min Liu, Laisheng Li, Jian Wu Diagnostics.2023; 13(8): 1442. CrossRef
Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma Yanjie Yang, Nan Du, Jingqin Ma, Zhijie Peng, Bo Zhou, Jiaze Yu, Xin Zhou, Wen Zhang, Zhiping Yan Journal of Hepatocellular Carcinoma.2023; Volume 10: 1897. CrossRef
Attenuation of binuclear hepatocytes in the paracancerous liver tissue is associated with short‐term recurrence of hepatocellular carcinoma post‐radical surgery Yifan Zhang, Nan Wang, Fengjie Hao, Yongjun Chen, Xiaochun Fei, Junqing Wang The FASEB Journal.2023;[Epub] CrossRef
Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients Tianying Ren, Xu Hou, Xin Zhang, Dongliang Chen, Juan Li, Yingnan Zhu, Zhiheng Liu, Dawei Yang Heliyon.2023; 9(11): e21906. CrossRef
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions Libin Dong, Xun Qiu, Fengqiang Gao, Kai Wang, Xiao Xu Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(6): 189016. CrossRef
Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area Joo Hyun Oh, Jonghyun Lee, Eileen L. Yoon, Soung Won Jeong, Soon Sun Kim, Young Eun Chon, Sang Bong Ahn, Dae Won Jun Cancers.2023; 16(1): 150. CrossRef
First
Prev
